PanINSULA - The next first commercially sustainable and therapeutically effective beta cell therapy for diabetes

Informazioni relative al progetto

PanINSULA

ID dell’accordo di sovvenzione: 828384

DOI

10.3030/828384

Progetto chiuso

Data della firma CE 19 Luglio 2018

Data di avvio 1 Agosto 2018

Data di completamento 30 Novembre 2018

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

PANCRYOS APS
Denmark

Periodic Reporting for period 1 - PanINSULA (PanINSULA - The next first commercially sustainable and therapeutically effective beta cell therapy for diabetes)

Periodo di rendicontazione: 2018-08-01 al 2018-11-30

Sintesi del contesto e degli obiettivi generali del progetto

Type 1 Diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stop producing insulin - the hormone that controls blood-sugar levels. Insulin therapy, CGMs and insulin pumps try to mimic the function of the beta cell and require the patient or a computer to perform many of the steps such as testing blood, evaluating the results and administering insulin. PanCryos is developing a next generation stem cell derived therapy, PanINSULA, to treat T1D naturally without the need for outside intervention. The overall objectives of the project are implementing a GMP-compliant production protocol and clinically validating PanINSULA.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

During Phase 1 PanCryos assessed both the technical and business feasibility of PanINSULA. A product development plan addressing production setup and clinical validation requirements to ensure PanINSULA market readiness was drafted. Third parties to participate in the product development were contacted. A market assessment (including assessment of market size, customers and competitors) was carried out, the business model was refined and financial projections were prepared.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Pancryos patented technology, in contrast to other available competing technologies, enables both purification and automation ensuring unparalleled safety and cost-efficient scalability and manufacturability of the final cell product PanINSULA which can then be delivered to T1D patients as a naturally-acting alternative to existing solutions such as insulin therapy, CGMs and insulin pumps which requires careful and constant management. PanINSULA commercialisation will improve the quality of life of millions of patients suffering from diabetes.

PanCryos